✦ LIBER ✦

Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy

✍ Scribed by Dushyant Verma; Hagop Kantarjian; Jianqin Shan; Susan O'Brien; Zeev Estrov; Guillermo Garcia-Manero; Charles Koller; Gautam Borthakur; Jorge Cortes

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 153 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The effect of interleukin 11 on thromboc

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

✍ Ahmed Aribi; Hagop Kantarjian; Charles Koller; Deborah Thomas; Stefan Faderl; Gu 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views

Practical advice for determining the rol

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

✍ Elias Jabbour; Susan Branford; Giuseppe Saglio; Dan Jones; Jorge E. Cortes; Hago 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB 👁 1 views

## Abstract Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are rapidly changing the treatment landscape for CML. In this review, the authors discuss currently available thera

Novel tyrosine kinase inhibitor therapy

Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia : No evidence for increased transplant-related toxicity

✍ Elias Jabbour; Jorge Cortes; Hagop Kantarjian; Sergio Giralt; Borje S. Andersson 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 1 views

## Abstract ## BACKGROUND. Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) are increasingly likely to have received a novel tyrosine kinase inhibitor (NTKI) after failing imatinib mesylate. It is unknown whether the use of these NTKI